A recent study showed improved long-term survival outcomes and QoL for patients with a B-cell malignancy receiving TKI therapy. READ MORE
A recent study showed improved long-term survival outcomes and QoL for patients with a B-cell malignancy receiving TKI therapy.
An analysis of over 39,000 patients with a certain B-cell malignancy showed improved survival outcomes after radiation therapy.
The high economic burden of B-cell malignancies on US commercial insurers may impact future reimbursement decisions.
Although some patients with DLBCL may be cured of their disease, risk of non-cancer causes of death is elevated in comparison with the general population.
The oncology nurses’ responsibility in monitoring and recognizing symptoms of CAR T-cell toxicities is especially important.
CD19-specific CAR T-cell therapy is more likely to be effective when given immediately after front-line therapy in patients with B-cell ALL.
New Consensus Guidelines for Hematological Malignancies, Prostate Cancer Immunotherapy Treatment Published
Current value frameworks issued by leading medical societies may not be easily generalizable to the treatment of hematologic malignancies.
Research in Review
The addition of a novel monoclonal antibody to ibrutinib significantly improves survival outcomes for patients with previously treated high-risk chronic lymphocytic leukemia.
An intravenous consolidation regimen developed for patients with chronic lymphocytic leukemia (CLL) was found to be safe and effective, according to a report in the European Journal of Hematology (2017;98:254-262).
Mutations in the BTK and PLCG2 genes have the potential to be used as a biomarker for relapse of chronic lymphocytic leukemia after treatment with ibrutinib.
Genomic profiling should be applied to patients with histiocytic disorders at diagnosis in order to guide targeted therapy.